A potential future area of investigation could also examine the effectiveness of second-line ipilimumab in BRAF-mutated melanoma patients after progression on first-line nivolumab or pembrolizumab and the comparative effectiveness between ipilimumab monotherapy and BRAFi/MEKi combination. Here, BRAF is linked to melanoma.